Hornberger John, Doberne Julie, Chien Rebecca
Cedar Associates LLC, Menlo Park, California 94025, USA.
Genet Test Mol Biomarkers. 2012 Jun;16(6):605-14. doi: 10.1089/gtmb.2011.0177. Epub 2012 Feb 2.
Since the late 1990 s, there has been an unprecedented growth in the development of new molecular and proteomic assays for clinical decision making. Despite the thousands of tests available, a standardized, well-defined, and coherent evaluation framework for these molecular assays is still lacking. We aim to summarize the publicly available appraisal criteria and to develop a succinct and accessible set of criteria that can provide a roadmap for the appraisal of gene-based laboratory developed tests (LDTs). We conducted a systematic literature review of the available molecular diagnostic framework in PubMed MD and CINAHL and identified 91 articles on existing appraisal criteria. We provided a summary of the historical appraisal system and developed an analysis of these appraisal systems, LDT-SynFRAME, which details the major criteria for evaluating molecular diagnostics in the clinical setting. Our goal with the LDT-SynFRAME system is to promote a well-informed dialog among all the stakeholders responsible for the development, approval, reimbursement, and use of new molecular classifiers.
自20世纪90年代末以来,用于临床决策的新型分子和蛋白质组学检测方法的开发取得了前所未有的增长。尽管有数千种检测方法可供使用,但这些分子检测方法仍缺乏一个标准化、定义明确且连贯的评估框架。我们旨在总结公开可用的评估标准,并制定一套简洁易懂的标准,为基于基因的实验室开发检测方法(LDT)的评估提供路线图。我们对PubMed MD和CINAHL中可用的分子诊断框架进行了系统的文献综述,共识别出91篇关于现有评估标准的文章。我们总结了历史评估系统,并对这些评估系统进行了分析,开发了LDT-SynFRAME,该系统详细阐述了临床环境中评估分子诊断的主要标准。我们使用LDT-SynFRAME系统的目标是促进所有负责新分子分类器开发、批准、报销和使用的利益相关者之间进行明智的对话。